analyz growth health
jack tool kit potenti growth contribut recent
trivia question mani new drug approv fda within
recent note report tool dx lab director survey say see interest
 dx weekli flu clue review ili flat w/w
barclay geograph end market tracker agil pmi tracker
q/q pmi tracker q/q thermo fisher pmi
tracker q/q water pmi tracker q/q
strengthen w/w chines yuan strengthen w/w japanes yen
hot topic week foundat medicin announc broad
companion diagnost relationship oncolog portfolio issu
billion senior note million rate due million
rate due proce use redeem billion outstand
senior note due merck keytruda combin two
chemotherapi drug success first line treatment lung cancer regardless
statu result publish studi tuesday
coverag univers finish week sinc last thursday tool
diagnost lab comparison
 week russel
nasdaq composit
stat week oncolog fda-approv therapi asset
clinic develop phase studi
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
pleas present barclay life scienc tool diagnost trivia question
week week ask question tool diagnost industri
would prefer dont look answer wont polic simpl answer
next week weekli
trivia question mani new drug approv fda within
last week answer custom labcorp denver-area retail locat
walgreen either new patient seen last year
jack tool kit life scienc tool diagnost
week answer question receiv client tri pick
topic respons dont pick question keep tri get
question potenti growth contribut health
use strateg partnership icon parexel privat preced
weve attempt quantifi potenti contribut growth health
larg strateg partnership background cover barclay analyst
geoff meacham announc would consolid biopharma servic provid
two icon parexel start began contribut
meaning result quickli report top client
compani result easili track partnership impact
growth icon parexel contribut increment revenu growth icon
parexel period estim outsourc revenu grew
aggreg admit addit compani
partnership includ privat inventiv syneo
complet thought
health pleas see
initi decemb
differenti growth
data initi overweight
pfizer outsourc revenu mm growth
part overweight thesi health compani strateg
partnership improv visibl sustain double-digit top line growth
health announc relationship takeda believ began contribut
revenu addit compani announc anoth partnership
larg biopharma compani expect began contribut revenu
manag said partnership similar size ramp
similarli unlik believ takeda chosen health sole
strateg partner cro servic
backlog new busi growth
analysi assum health takeda partnership follow
ramp combin icon parexel partnership combin
icon parexel takeda chosen health sole strateg partner
ramp appli takeda partnership base icon parexel revenu
gener percentag total report spend
report spend icon parexel ramp steadili around total
run-rat around appli ramp takeda
histor consensu get estim
contribut health result given manag state
partnership similar size trajectori takeda partnership assum
contribut start assum similar trajectori take-away
strateg partnership potenti contribut meaning
growth addit believ forecast could
ultim prove conserv given ramp impli core busi would
moder project chart show potenti contribut
section summar recent research public pleas contact us
copi
interest pama-driven outsourc near-term dx trend appear
fifth quarterli lab director survey continu build proprietari
longitudin data impact protect access medicar act pama
hospit lab oper well diagnost volum growth purchas decis
survey particularli intrigu first perform sinc public
prelim final medicar rate pama result show
appreci medicar cut jan believ tip balanc
toward greater outsourc respond indic neg pama impact
increas steadili sinc survey respons lab director evalu
staf reduct respons increas invest autom
reduct test menu said would outsourc test vs w/o
pama believ re-evalu lab servic platform invest mani
hospit on-going sever year consolid could top
record level activ took place pama one factor drive chang
payor patient consumer favor shift toward nation lab favor labcorp
top pick
 life scienc tool diagnost weekli flu clue review ili
publish edit barclay health flu clue review
weekli report track sever progress flu season follow three
metric percentag patient visit physician attribut
influenza-lik ill ili versu baselin averag influenza-lik ill defin
fever exceed degre plu either cough sore throat percentag death
attribut pneumonia influenza versu baselin averag number
type posit influenza test conduct clinic laboratori report
partnershipsclin research ex-partnershipsprah clinic research rev barclay life scienc tool diagnost
center diseas control cdc us world organ
nation respiratori viru surveil nrevss edit examin data
week end januari week week flu season
obtain data cdc feder govern agenc part
foundat medicin announc broad companion diagnost relationship
oncolog portfolio
issu billion senior note million rate due
million rate due proce use redeem billion
merck keytruda combin two chemotherapi drug success first
line treatment lung cancer regardless statu result publish studi
help investor gaug end market activ develop barclay pmi
tracker tracker repres weighted-averag growth agil
thermo fisher underli geographi use pmi data ism unit
state markit intern one-quart lag barclay agil
thermo fisher pmi tracker correl
organ growth follow quarter respect
pleas reach us would like copi barclay pmi tracker
decemb barclay agil pmi tracker regist
q/q approxim agil revenu gener outsid unit
state exposur asia europ compani barclay
agil pmi end market tracker one-quart lead correl
compani organ growth rate notic trend agil geograph
exposur growth past quarter far back intern data
track believ pmi tracker best use one-quart lead indic
expansionari tracker perform start year give us good convict
agil abil hit initi guidanc organ growth
barclay pmi tracker regist q/q
approxim compani revenu gener outsid unit state
signific exposur emerg market revenu barclay
perkinelm pmi end market tracker one-quart lead correl
compani organ growth rate notic trend perkinelm
geograph exposur growth past quarter far back intern
data track believ pmi tracker best use one-quart lead
indic note recent lower guidanc
barclay thermo fisher pmi tracker regist q/q
approxim thermo fisher revenu gener outsid unit state
exposur china revenu germani uk amongst
other barclay thermo fisher end market tracker one-quart lead
correl compani organ growth rate optic notic
trend thermo fisher geograph exposur growth past quarter
far back intern data track believ pmi tracker best use
one-quart lead indic note solid pmi tracker perform
similar thermo fisher organ growth guidanc
barclay water pmi tracker regist q/q approxim
revenu gener outsid unit state exposur europ
revenu asia amongst other barclay water end market
tracker one-quart lead correl compani organ growth
rate optic notic trend geograph exposur
growth past quarter far back intern data track
believ pmi tracker best use one-quart lead indic note
expansionari read pmi tracker perform similar expect
organ growth repres growth upper end life
vi price perform valuat updat
coverag univers finish week sinc last thursday tool
diagnost lab comparison
week russel
composit best perform stock group
follow contrast worst perform
stock broadli speak week posit stock
increas stock decreas current level enterpris valu tool
trade ebitda diagnost trade lab
trade
enterpris valu life scienc tool compani trade near twelv
month ntm ebitda estim rang varian
compar five year averag ntm ebitda ten year averag
ntm ebitda past five year group broadli trade within rang
forward ebitda
enterpris valu diagnost compani trade near twelv month
ntm ebitda estim rang
compar five-year averag ntm ebitda ten-year averag
ntm ebitda past five year group broadli trade within rang
forward ebitda
enterpris valu cro compani trade near twelv month ntm
ebitda estim rang charl river health
compar five-year averag ntm ebitda ten-year averag
ntm ebitda past five year group broadli trade within rang
forward ebitda
enterpris valu lab compani trade near twelv month ntm
ebitda estim compar five-year averag ntm ebitda ten-
year averag ntm ebitda past five year group broadli trade
within rang forward ebitda
vii metric coverag univers
price target base multipl ebitda estim materi discuss valuat methodolog avail upon request full disclosur
cover compani includ detail company-specif valuat methodolog risk pleas refer http //publicresearch barcap com
thomson one compani document barclay research repres cash ep rest adjust ep inc stock comp
note barclay research estim ghdx iclr lh prxl
remaind consensu
note barclay research estim ghdx iclr lh prxl
remaind consensu
note barclay research estim ghdx iclr lh prxl
remaind consensu
viii stat week
oncolog fda-approv therapi asset clinic develop
phase studi
ix week life scienc tool diagnost
section present news summari relev articl past week
foundat medicin pfizer announc broad partnership develop companion
diagnost oncolog portfolio tuesday foundat medicin announc
compani enter broad partnership partnership focus
develop regulatori support commerci companion diagnost
cdx includ updat foundationon cdx foundationon cdx
foundat medicin fda-approv comprehens genom profil cgp assay
solid tumor incorpor multipl companion diagnost also benefit
access foundationinsight foundat medicin data analyt platform facilit
novel biomark discoveri optim clinic trial design
merck keytruda extend lung cancer surviv combin trial tuesday merck
announc pivot phase trial
pembrolizumab merck therapi combin pemetrex alimta
cisplatin carboplatin first-lin treatment patient metastat non-
squamou non-smal cell lung cancer nsclc met dual primari endpoint overal
surviv os progression-fre surviv base interim analysi conduct
independ data monitor committe treatment keytruda combin
pemetrex plu platinum chemotherapi result significantli longer os
pemetrex plu platinum chemotherapi alon
announc offer billion senior note tuesday
announc launch subject market condit privat offer
billion aggreg princip amount senior note alloc
addit senior note due new senior note due
senior note due new note issu pursuant new indentur
execut close offer addit note new
note unsecur oblig compani guarante certain
subsidiari intend use proce offer avail cash
includ fund secur revolv credit facil redeem outstand
senior note due aggreg origin princip amount billion
pleas reach us barclay sale repres sign-up
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
laboratori corp america hldg lh usd overweight/neutr a/cd/ce/d/j/k/l/m/n
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
